GLP-1 Medications Explained: A Beginner's Guide for Filipino Patients
Key takeaways
- GLP-1 stands for glucagon-like peptide-1, a natural hormone produced in the gut after meals.
- GLP-1 receptor agonists bind to the same receptors that native GLP-1 binds, mimicking its action.
- The current GLP-1 receptor agonists, in approximate order of approval and prominence:
- For the Filipino patient comparing options, the published trial outcomes at typical doses:
- GLP-1 medications share a broadly similar side-effect profile because they share the GLP-1 receptor mechanism.
GLP-1 medications have moved from niche endocrinology prescription into mainstream Filipino conversation over the past three years. Patients walking into registered Philippine pharmacy chains now ask for branded semaglutide by name. BGC weight-management clinics book months in advance. The category is large enough that the casual user encounters terms (semaglutide, tirzepatide, GLP-1 agonist, dual receptor agonist, triple agonist) without a clear framework for what they mean. This guide is the foundational reading for Filipino patients new to the GLP-1 category.
We cover what GLP-1 is in the body, how the drugs work, which medications are available globally and which have reached the Philippines, the differences between brands and molecules, the broad side-effect profile, and the verification step that applies to any product sourced outside registered pharmacy channels.
For deep dives, see our Tirzepatide Philippines complete guide, tirzepatide vs branded semaglutide vs high-dose branded semaglutide, branded semaglutide Philippines complete guide, and Semaglutide Philippines.
What GLP-1 is
GLP-1 stands for glucagon-like peptide-1, a natural hormone produced in the gut after meals. It is part of the incretin family of hormones, which signal the body that food has arrived and trigger metabolic responses. GLP-1's main physiological actions:
- Stimulates insulin release from pancreatic beta cells in response to elevated blood glucose.
- Suppresses glucagon release from pancreatic alpha cells.
- Slows gastric emptying, prolonging the sensation of fullness after meals.
- Acts on the brain to reduce appetite and food intake.
- Has effects on cardiovascular and other tissues beyond direct metabolic action.
The combination of these effects produces the clinical pattern that GLP-1 medications target: improved blood-glucose control plus reduced food intake plus prolonged satiety, which together drive weight loss and improved diabetes control.
Native GLP-1 has a short half-life (a few minutes) because it is rapidly broken down by an enzyme called DPP-4. GLP-1 medications are synthetic analogues designed to resist DPP-4 breakdown, which extends their half-life and allows therapeutic dosing.
How GLP-1 medications work
GLP-1 receptor agonists bind to the same receptors that native GLP-1 binds, mimicking its action. The synthetic modifications to extend half-life produce molecules that:
- Bind GLP-1 receptors with similar affinity as native GLP-1.
- Resist DPP-4 breakdown, allowing days-to-weeks of activity.
- Are dosed once weekly (most current generation) or daily (older liraglutide).
- Produce systemic effects at the gut, pancreas, and brain receptors.
Some newer molecules also activate other receptors:
- Tirzepatide: GLP-1 + GIP dual agonist. GIP is another incretin hormone with somewhat different metabolic effects.
- Retatrutide (investigational): GLP-1 + GIP + glucagon triple agonist. Adds glucagon receptor activation, which increases hepatic energy expenditure.
The trend in drug development is toward multi-receptor agonists that combine several mechanisms for larger weight-loss and metabolic effects.
The GLP-1 medications in 2026
The current GLP-1 receptor agonists, in approximate order of approval and prominence:
Liraglutide
- Brands: diabetes-indicated liraglutide (diabetes), branded liraglutide (weight loss).
- Manufacturer: the manufacturer.
- Dosing: daily subcutaneous injection.
- Approval: diabetes-indicated liraglutide 2010 (US), branded liraglutide 2014.
- Philippine availability: branded liraglutide available with prescription at hospital pharmacies and select retail.
Semaglutide
- Brands: branded semaglutide (diabetes injectable), high-dose branded semaglutide (weight loss injectable), branded oral semaglutide (diabetes oral tablet).
- Manufacturer: the manufacturer.
- Dosing: weekly injection (branded semaglutide, high-dose branded semaglutide) or daily tablet (branded oral semaglutide).
- Approval: branded semaglutide 2017, branded oral semaglutide 2019, high-dose branded semaglutide 2021 (US).
- Philippine availability: branded semaglutide widely at major Philippine retail pharmacy chains; branded oral semaglutide at select branches; high-dose branded semaglutide via specialty importers only.
Tirzepatide
- Brands: branded tirzepatide (diabetes), weight-management tirzepatide (weight loss).
- Manufacturer: the manufacturer.
- Dosing: weekly injection.
- Approval: branded tirzepatide 2022, weight-management tirzepatide 2023 (US).
- Philippine availability: branded tirzepatide at major Philippine retail pharmacy chains; weight-management tirzepatide via specialty channels.
Older or less common
- Exenatide (Byetta, Bydureon): older GLP-1 agonist, declining in use.
- Dulaglutide (Trulicity): weekly injection, used for diabetes.
- Albiglutide (Tanzeum): discontinued in most markets.
Investigational
- Retatrutide (the manufacturer): triple agonist in late-stage trials.
- Cagrilintide + semaglutide (investigational cagrilintide-semaglutide combination, the manufacturer): in development.
- Various other multi-receptor candidates from major pharmaceutical companies.
What GLP-1 medications produce: weight loss outcomes
For the Filipino patient comparing options, the published trial outcomes at typical doses:
| Medication | Trial | Dose | Duration | Mean weight reduction |
|---|---|---|---|---|
| Liraglutide | SCALE-Obesity | 3 mg daily | 56 weeks | 8.0% |
| Semaglutide | STEP-1 | 2.4 mg weekly | 68 weeks | 14.9% |
| Tirzepatide | SURMOUNT-1 | 15 mg weekly | 72 weeks | 22.5% |
| Retatrutide | Phase 2 (Jastreboff 2023) | 12 mg weekly | 48 weeks | 24.2% |
The trend: each newer molecule produces larger weight-loss effects than the previous generation. The differences are clinically meaningful.
For the comparison framework specifically, see tirzepatide vs branded semaglutide vs high-dose branded semaglutide.
Side effects: what to expect
GLP-1 medications share a broadly similar side-effect profile because they share the GLP-1 receptor mechanism. The most common, in approximate order of frequency:
- Nausea: very common, particularly during titration and at higher doses. Typically improves over 2 to 4 weeks at a stable dose.
- Diarrhoea or constipation: common.
- Vomiting: less common, dose-related.
- Fatigue: common in early weeks, improves with adaptation.
- Reduced appetite: this is the mechanism, not a side effect.
- Injection-site reactions: rare, typically mild.
- Decreased food enjoyment: some users report changes in food preferences and reduced enjoyment of high-fat or high-sugar foods.
Less common but more serious:
- Acute pancreatitis: rare, but warrants drug discontinuation if confirmed.
- Gallbladder disease: increased risk with rapid weight loss.
- Black-box warning for thyroid C-cell tumours: derived from rodent studies; no clear human signal but contraindication for patients with personal or family MTC or MEN2 history.
For the deep dive on tirzepatide-specific side effects, see tirzepatide side effects.
Who GLP-1 medications are for
The two main on-label indications:
Type 2 diabetes management: improve glycaemic control. Most current PH prescriptions for branded semaglutide and branded tirzepatide are written under this indication.
Chronic weight management (in patients with obesity or overweight with comorbidities): on-label for high-dose branded semaglutide, branded liraglutide, and weight-management tirzepatide; off-label use of branded semaglutide for this indication is widespread.
In Filipino practice, off-label use for weight management is the dominant pattern because high-dose branded semaglutide and weight-management tirzepatide have limited PH distribution while branded semaglutide and branded tirzepatide are widely available.
Patient profiles where GLP-1 medications generally make sense:
- BMI greater than 30 (obesity) with weight-management goal.
- BMI 27 to 30 (overweight) with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidaemia, sleep apnoea).
- Type 2 diabetes inadequately controlled on metformin or other first-line options.
Patient profiles where GLP-1 medications are not the right fit:
- Modest weight-loss goals achievable through lifestyle alone.
- BMI in the normal range with body-image-driven weight-loss goals.
- Personal or family history of MTC or MEN2.
- Active gastroparesis or severe GI motility disorders.
- Pregnancy (no safety data; conservative practice is to discontinue).
- Active pancreatitis history.
Philippine pricing landscape
| Medication | Typical monthly cost in PH (registered pharmacy) |
|---|---|
| branded liraglutide (liraglutide) | PHP 28,000 to 38,000 |
| branded semaglutide 1 mg (semaglutide) | PHP 14,000 to 18,000 |
| branded semaglutide 2 mg (semaglutide) | PHP 18,000 to 23,000 |
| high-dose branded semaglutide 2.4 mg (semaglutide, specialty) | PHP 30,000 to 38,000 |
| branded tirzepatide 7.5 mg (tirzepatide) | PHP 24,000 to 30,000 |
| branded tirzepatide 15 mg (tirzepatide) | PHP 32,000 to 38,000 |
| branded oral semaglutide (oral semaglutide) | PHP 4,500 to 15,000 (depends on dose) |
Grey-market pricing across all categories runs 30 to 60% below the registered pharmacy floor, with corresponding authentication and quality risk.
Authentication: the universal verification question
Across all GLP-1 medications, the verification question is the same. Visual checks (holographic seal, lot numbers across multiple locations, country of manufacture, embossing quality, dose-window clarity) catch obvious counterfeits but not sophisticated ones. Analytical chemistry catches both.
Lumen Labs runs:
- HPLC purity at the relevant absorbance wavelength.
- LC-MS identity against the published peptide mass.
- Quantitation against label dose.
- Optional endotoxin and microbial limits.
The output is a certificate of analysis confirming what the submitted product actually contains.
For the visual authentication checklist, see how to spot fake tirzepatide and branded semaglutide.
Bottom line on GLP-1 medications for Filipinos
GLP-1 medications are a real and effective drug class for type 2 diabetes management and chronic weight management. The evidence base is strong, the side-effect profile is well-characterised, and the brand options span a price-effect-convenience spectrum.
Filipino patients new to the category should understand the molecule landscape (liraglutide, semaglutide, tirzepatide, soon retatrutide), the brand mapping (branded liraglutide, branded semaglutide, high-dose branded semaglutide, branded tirzepatide, weight-management tirzepatide), the dosing schedules (daily, weekly), and the practical pricing across registered pharmacy channels.
For any product sourced through registered Philippine pharmacy channels with a valid prescription, the authentication question is largely solved. For anything else, independent third-party laboratory analysis converts label claim into measured data.
Disclaimer: Lumen Labs provides chemical analysis of submitted samples for harm-reduction and quality-verification purposes. We are not a substitute for medical care. GLP-1 medications are prescription products; consult a qualified Philippine licensed physician before starting, adjusting, or stopping any therapy.